STAA News and Press, STAAR Surgical Company From 07/12/23

2023-07-12 06:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy underperf...

2023-06-07 16:32:14 ET William Blair has lowered its rating on STAAR Surgical ( NASDAQ: STAA ) to market perform citing a potential delay in US market inflection for the implantable lens maker. "Overall, while we continue to think 10%-plus penetration is achievable in the United...

2023-05-30 17:00:54 ET Summary Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 metrics offered positive read-throughs for the compa...

2023-05-26 23:35:56 ET Summary STAAR Surgical is on the cusp of an acceleration in earnings and growth courtesy of its entrance into the US market. It is profitable, generates positive cash flow, and has zero real debt. It's not cheap, but growth stocks never are in the true s...

2023-05-23 22:30:17 ET Summary STAAR Surgical came in with another reasonably strong first quarter, with topline growth a standout. Investors response to the Q1 update has been mute suggesting no revised expectations. Starting valuations are unsupportive, especially for a re-r...

EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome, announced today sponsorship of the Jonas Brothers’ The Tour in North America, which begins Au...

2023-05-03 22:51:07 ET STAAR Surgical Company (STAA) Q1 2023 Earnings Conference Call May 03, 2023, 04:30 PM ET Company Participants Brian Moore - VP of Investor, Media Relations and Corporate Development Tom Frinzi - President and CEO Patrick Williams - CFO ...

2023-05-03 16:04:20 ET STAAR Surgical press release ( NASDAQ: STAA ): Q1 GAAP EPS of $0.05 beats by $0.06 . Revenue of $73.5M (+16.3% Y/Y) beats by $7.28M . Cash, Cash Equivalents and Investments Available for Sale Ended the Quarter at $217.3 Million Gross ...

Q1 2023 Net Sales of $ 73.5 Million ; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y STAAR Surgical Company (NASDAQ: STAA), a leading developer, manu...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3, 2023 after the market close. STAAR wi...